WIPFLER PETER
Department of Neurology
Publications
|
Researcher Profile
93 Publications
2023
Journal Articles
Immunomodulatory Aspects of Therapeutic Plasma Exchange in Neurological Disorders-A Pilot Study.
Foettinger, F; Pilz, G; Wipfler, P; Harrer, A; Kern, JM; Trinka, E; Moser, T;
Int J Mol Sci. 2023; 24(7):
Full papers/articles (Journal)
Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
Seiberl, M; Feige, J; Hilpold, P; Hitzl, W; Machegger, L; Buchmann, A; Khalil, M; Trinka, E; Harrer, A; Wipfler, P; Moser, T;
Int J Mol Sci. 2023; 24(4):
Full papers/articles (Journal)
2022
Journal Articles
Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.
Bsteh, G; Assar, H; Gradl, C; Heschl, B; Hiller, MS; Krajnc, N; Di Pauli, F; Hegen, H; Traxler, G; Leutmezer, F; Wipfler, P; Zulehner, G; Guger, M; Enzinger, C; Berger, T;
Eur J Neurol. 2022;
Full papers/articles (Journal)
Impact of vaccination on COVID-19 outcome in multiple sclerosis.
Bsteh, G; Gradl, C; Heschl, B; Hegen, H; Di Pauli, F; Assar, H; Leutmezer, F; Traxler, G; Krajnc, N; Zulehner, G; Hiller, MS; Rommer, P; Wipfler, P; Guger, M; Enzinger, C; Berger, T;
Eur J Neurol. 2022;
Full papers/articles (Journal)
Humoral Response to SARS-CoV-2 Antigen in Patients Treated with Monoclonal Anti-CD20 Antibodies: It Is Not All about B Cell Recovery.
Feige, J; Berek, K; Seiberl, M; Hilpold, P; Hitzl, W; Di Pauli, F; Hegen, H; Deisenhammer, F; Trinka, E; Harrer, A; Wipfler, P; Moser, T;
Neurol Int. 2022; 14(4): 943-951.
Full papers/articles (Journal)
The CXCL13/CXCR5 Immune Axis in Health and Disease-Implications for Intrathecal B Cell Activities in Neuroinflammation
Harrer, C; Otto, F; Radlberger, RF; Moser, T; Pilz, G; Wipfler, P; Harrer, A
CELLS-BASEL. 2022; 11(17): 2649
Reviews
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study.
Moser, T; OSullivan, C; Otto, F; Hitzl, W; Pilz, G; Schwenker, K; Mrazek, C; Haschke-Becher, E; Trinka, E; Wipfler, P; Harrer, A;
Ther Adv Neurol Disord. 2022; 15: 17562864221092092
Full papers/articles (Journal)
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser, T; Otto, F; OSullivan, C; Hitzl, W; Pilz, G; Harrer, A; Trinka, E; Wipfler, P;
Mult Scler Relat Disord. 2022; 59: 103560
Full papers/articles (Journal)
Tick-Borne Encephalitis Virus RNA Found in Frozen Goatxxxs Milk in a Family Outbreak
Mylonaki, E; Seiberl, M; Jones, N; Bernhard, H; Otto, F; Pilz, G; Trinka, E; Wipfler, P
INT J MOL SCI. 2022; 23(19): 11632
Case Reports
Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
O Sullivan, C; Zach, F; Moser, T; Pilz, G; Harrer, A; Trinka, E; Enzinger, C; Pfaff, JAR; Wipfler, P;
J Neurol. 2022; 269(2):616-618
Letters
Conference papers, proceedings, abstracts
Long-term outcome after COVID-19 infection in multiple sclerosis: a matched-controlled study
Bsteh, G; Assar, H; Gradl, C; Heschl, B; Hiller, M; Krajnc, N; Di Pauli, F; Hegen, H; Traxler, G; Wipfler, P; Guger, M; Enzinger, C; Berger, T
EUR J NEUROL. 2022; 29: 289-289.
Abstracts (Journal)
Long-term outcome after COVID-19 infection in multiple sclerosis: a matched-controlled study in a nation-wide Austrian registry
Bsteh, G; Assar, H; Gradl, C; Heschl, B; Hiller, MS; Krajnc, N; Di Pauli, F; Hegen, H; Traxler, G; Wipfler, P; Guger, M; Enzinger, C; Berger, T
MULT SCLER J. 2022; 28(3_SUPPL): 487-488.
Abstracts (Journal)
COVID-19 in multiple sclerosis: update from the nation-wide Austrian registry
Bsteh, G; Gradl, C; Assar, H; Heschl, B; Hegen, H; Di Pauli, F; Leutmezer, F; Traxler, G; Zulehner, G; Rommer, P; Hiller, MS; Krajnc, N; Wipfler, P; Guger, M; Enzinger, C; Berger, T
MULT SCLER J. 2022; 28(3_SUPPL): 210-211.
Abstracts (Journal)
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications
Moser, T; Otto, F; Pilz, G; Wipfler, P
EUR J NEUROL. 2022; 29: 395-395.
Abstracts (Journal)
2021
Journal Articles
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
Bsteh, G; Assar, H; Hegen, H; Heschl, B; Leutmezer, F; Di Pauli, F; Gradl, C; Traxler, G; Zulehner, G; Rommer, P; Wipfler, P; Guger, M; Enzinger, C; Berger, T;
PLoS One. 2021; 16(7): e0255316
Full papers/articles (Journal)
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Bsteh, G; Durauer, S; Assar, H; Hegen, H; Heschl, B; Leutmezer, F; Di Pauli, F; Gradl, C; Traxler, G; Zulehner, G; Rommer, P; Wipfler, P; Guger, M; Hoftberger, R; Enzinger, C; Berger, T
Mult Scler. 2021; 27(14):2209-2218
Full papers/articles (Journal)
The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF
Harrer, C; Otto, F; Pilz, G; Haschke-Becher, E; Trinka, E; Hitzl, W; Wipfler, P; Harrer, A
FLUIDS BARRIERS CNS. 2021; 18(1): 40
Full papers/articles (Journal)
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
Moser, T; OSullivan, C; Puttinger, C; Feige, J; Pilz, G; Haschke-Becher, E; Cadamuro, J; Oberkofler, H; Hitzl, W; Harrer, A; Kraus, J; Trinka, E; Wipfler, P;
Biomedicines. 2021; 9(11):
Full papers/articles (Journal)
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser, T; Seiberl, M; Feige, J; Bieler, L; Radlberger, RF; OSullivan, C; Pilz, G; Harrer, A; Schwenker, K; Haschke-Becher, E; Machegger, L; Grimm, J; Redlberger-Fritz, M; Buchmann, A; Khalil, M; Kvas, E; Trinka, E; Wipfler, P;
Front Immunol. 2021; 12:718895
Full papers/articles (Journal)
Role and Relevance of Cerebrospinal Fluid Cells in Diagnostics and Research: State-of-the-Art and Underutilized Opportunities.
Otto, F; Harrer, C; Pilz, G; Wipfler, P; Harrer, A;
Diagnostics (Basel). 2021; 12(1):
Reviews
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.
Radlberger, RF; Sakic, I; Moser, T; Pilz, G; Harrer, A; Wipfler, P;
Mult Scler Relat Disord. 2021; 48:102727
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
COVID-19 severity and mortality in multiple sclerosis do not depend on immunotherapy: insights from a nationwide Austrian Registry
Bsteh, G; Assar, H; Hegen, H; Heschl, B; Leutmezer, F; Di Pauli, F; Gradl, C; Traxler, G; Zulehner, G; Rommer, P; Wipfler, P; Guger, M; Enzinger, C; Berger, T
MULT SCLER J. 2021; 27(2_SUPPL): 59-60.
Abstracts (Journal)
2020
Journal Articles
Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
Feige, J; Schernthaner, C; Wipfler, P; Sellner, J;
Mult Scler Relat Disord. 2020; 38: 101515
Case Reports
Neurological complications associated with influenza in season 2017/18 in Austria- a retrospective single center study.
Mylonaki, E; Harrer, A; Pilz, G; Stalzer, P; Otto, F; Trinka, E; Wipfler, P;
J Clin Virol. 2020; 127: 104340
Full papers/articles (Journal)
Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction.
Pilz, G; Sakic, I; Wipfler, P; Kraus, J; Haschke-Becher, E; Hitzl, W; Trinka, E; Harrer, A;
Fluids Barriers CNS. 2020; 17(1): 7
Full papers/articles (Journal)
Beyond LNB: Real life data on occurrence and extent of CSF CXCL13 in neuroinflammatory diseases.
Pilz, G; Steger, R; Wipfler, P; Otto, F; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A;
J Neuroimmunol. 2020; 338:577087
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Ongoing disease activity despite depletion of memory B cells under cladribine in MS: a case report.
Radlberger, RF; Moser, T; Schwenker, K; Harrer, A; Wipfler, P;
Ongoing disease activity despite depletion of memory B cells under cladribine in MS: a case report.. 2020; -ÖGN 2020 – 17. Jahrestagung der österreichischen Gesellschaft für Neurologie, Salzburg, 20.-21. September, 2020
; 20.-21.09.2020; SALZBURG.
Abstracts (Journal)
2019
Journal Articles
Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study.
Pilz, G; Wipfler, P; Otto, F; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A;
J Neuroinflammation. 2019; 16(1): 13
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Initial real-life experience with ocrelizumab in patients with relapsing-remitting and primary progressive multiple sclerosis in Salzburg, Austria
Feige, J; Moser, T; Nagy, Z; Otto, F; Wipfler, P; Trinka, E; Sellner, J;
EUR J NEUROL. 2019; 26: 489-489.
Abstracts (Journal)
Long-term follow-up of delayed high-grade atrioventricular block with pacemaker placement during fingolimod treatment for relapsing-remitting multiple sclerosis
Feige, J; Wipfler, P; Schernthaner, C; Sellner, J;
EUR J NEUROL. 2019; 26: 751-751.
Abstracts (Journal)
Coexpression analysis of alpha-4 and beta-1 reveals VLA4-related subset heterogeneity and the VLA4(hi) phenotype associated with JCV seropositivity
Harrer, A; Frommrich, M; Moser, T; Federspieler, A; Wipfler, P; Afazel, S; Kraus, J; Haschke-Becher, E; Sellner, J
MULT SCLER J. 2019; 25: 447-447.
Abstracts (Journal)
2018
Journal Articles
The Viral Hypothesis of Mesial Temporal Lobe Epilepsy - Is Human Herpes Virus-6 the Missing Link? A systematic review and meta-analysis.
Wipfler, P; Dunn, N; Beiki, O; Trinka, E; Fogdell-Hahn, A;
Seizure. 2018; 54:33-40
Full papers/articles (Journal)
2017
Journal Articles
Human Herpesvirus 6B Induces Hypomethylation on Chromosome 17p13.3, Correlating with Increased Gene Expression and Virus Integration
Engdahl, E; Dunn, N; Niehusmann, P; Wideman, S; Wipfler, P; Becker, AJ; Ekstrom, TJ; Almgren, M; Fogdell-Hahn, A
J VIROL. 2017; 91(11): UNSP e02105-16
Notes
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Full papers/articles (Journal)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban, X; Hauser, SL; Kappos, L; Arnold, DL; Bar-Or, A; Comi, G; de Seze, J; Giovannoni, G; Hartung, HP; Hemmer, B; Lublin, F; Rammohan, KW; Selmaj, K; Traboulsee, A; Sauter, A; Masterman, D; Fontoura, P; Belachew, S; Garren, H; Mairon, N; Chin, P; Wolinsky, JS;
N Engl J Med. 2017; 376(3):209-220
Full papers/articles (Journal)
Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome.
Pilz, G; Wipfler, P; Schwarte, O; Golaszewski, S; McCoy, M; Haschke-Becher, E; Hartung, HP; Kraus, J;
J Neurol. 2017; 264(4): 799-801.
Letters
Conference papers, proceedings, abstracts
The immune receptor expression pattern in peripheral-blood associated with JCV seropositivity in patients with multiple sclerosis is not affected by natalizumab
Harrer, A; Frommrich, M; Moser, T; Afazel, S; Haschke-Becher, E; Wipfler, P; Sellner, J
MULT SCLER J. 2017; 23: 337-338.
Abstracts (Journal)
Automated brain tissue and lesion segmentation in multiple sclerosis: A feasibility study in the state of Salzburg
Varosanec, M; Marschallinger, R; Karamyan, A; Sellner, J; Oppermann, K; Golaszewski, SM; Wipfler, P; McCoy, MR; Trinka, E
EUR J NEUROL. 2017; 24: 429-430.
Abstracts (Journal)
2016
Journal Articles
Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study.
Karamyan, A; Dünser, MW; Wiebe, DJ; Pilz, G; Wipfler, P; Chroust, V; Novak, HF; Hauer, L; Trinka, E; Sellner, J;
PLoS One. 2016; 11(5):e0155795
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Evidence of gender differences for initiation of therapy escalation in multiple sclerosis
Karamyan, A; Oppermann, K; Bacher, C; Otto, F; Pilz, G; Wipfler, P; Chroust, V; Sellner, J
MULT SCLER J. 2016; 22: 723-723.
Abstracts (Journal)
Prevalence and predictors of sexual dysfunction in multiple sclerosis: a cross-sectional study
Otto, F; Bacher, C; Chroust, V; Karamyan, A; Oppermann, K; Reisp, M; Pilz, G; Wipfler, P; Sellner, J
MULT SCLER J. 2016; 22: 727-727.
Abstracts (Journal)
2015
Journal Articles
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer, A; Pilz, G; Wipfler, P; Oppermann, K; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J;
Clin Exp Immunol. 2015; 180(3):383-392
Full papers/articles (Journal)
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer, A; Wipfler, P; Pilz, G; Oppermann, K; Haschke-Becher, E; Afazel, S; Kraus, J; Trinka, E; Sellner, J;
Int J Mol Sci. 2015; 16(9): 21832-21845.
Full papers/articles (Journal)
Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukencephalopathy with an excellent outcome
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Rispens, T; van der Kleij, D; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clinical and Experimental Neuroimmunology. 2015;
Case Reports
Conference papers, proceedings, abstracts
Natural killer cell redistribution during short-term treatment with fingolimod in multiple sclerosis
Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Kraus, J; Trinka, E; Sellner, J; Wipfler, P
MULT SCLER J. 2015; 21: 447-447.
Abstracts (Journal)
Enhanced migration of CD56(bright) NK cells across hCMEC/D3 in interferon-beta-1a treated multiple sclerosis patients
Harrer, A; Wanek, J; Oppermann, K; Wimmer, M; Zauner, R; Couraud, PO; Romero, IA; Weksler, B; Afazel, S; Haschke-Becher, E; Wipfler, P; Pilz, G; Trinka, E; Sellner, J; Kraus, J
MULT SCLER J. 2015; 21: 321-322.
Abstracts (Journal)
Characteristics, causes of admission and short-term mortality of multiple sclerosis patients at the neurological intensive care unit
Karamyan, A; Pilz, G; Wipfler, P; Novak, H; Trinka, E; Sellner, J
MULT SCLER J. 2015; 21: 722-723.
Abstracts (Journal)
2014
Journal Articles
A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with reduced therapy efficiency under natalizumab
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Sellner, J; Deisenhammer, F; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2014; 38(1): 17-23.
Full papers/articles (Journal)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Sellner, J; Trinka, E; Kraus, J;
Acta Neurol Scand. 2014; 129(3):e12-e15
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Natalizumab and fingolimod differentially impact the alpha-4/beta-1 and alpha-L/beta-2 expression-related subset diversity of T-cells
Harrer, A; Oppermann, K; Wanek, J; Pilz, G; Wipfler, P; Sellner, J; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2014; 20: 333-333.
Abstracts (Journal)
2013
Journal Articles
Tumefactive MS lesions under fingolimod: a case report and literature review.
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J;
Neurology. 2013; 81(19): 1654-1658.
Full papers/articles (Journal)
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner, J; Koczi, W; Harrer, A; Oppermann, K; Obregon-Castrillo, E; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clin Exp Immunol. 2013; 173(3):381-389
Full papers/articles (Journal)
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.
Wipfler, P; Heikkinen, A; Harrer, A; Pilz, G; Kunz, A; Golaszewski, SM; Reuss, R; Oschmann, P; Kraus, J;
J Neurol. 2013; 260(1):221-227
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Shift in the CD4+/CD8+ratio of cerebrospinal fluid T cells independent from free or cell-bound natalizumab
Harrer, A; Oppermann, K; Pizl, G; Wipfler, P; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 451-452.
Abstracts (Journal)
Flow-cytometry and the detection of natalizumab-neutralizing antibodies in multiple sclerosis
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Holl, B; Deisenhammer, F; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 500-501.
Abstracts (Journal)
2012
Journal Articles
Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy.
Broussalis, E; Hutterer, M; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Haschke-Becher, E; Golaszewski, S; Schönauer, U; Weis, S; Killer-Oberpfalzer, M; Mc Coy, M; Trinka, E; Kraus, J;
Acta Neurol Scand. 2012; 126(3):e11-e16
Case Reports
Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis
Harrer, A; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, L; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 377-382.
Full papers/articles (Journal)
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Hitzl, W; Wipfler, P; Sellner, J; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
PLoS One. 2012; 7(2):e31784
Full papers/articles (Journal)
Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Holl, B; Oppermann, K; Golaszewski, SM; Harrer, A
LABORATORIUMSMEDIZIN. 2012; 36(6): 389-396.
Reviews
Biomarkers of Inflammation and Endothelial Dysfunction in Stroke with and without Sleep Apnea
Kunz, AB; Kraus, J; Young, P; Reuss, R; Wipfler, P; Oschmann, P; Blaes, F; Dziewas, R
CEREBROVASC DIS. 2012; 33(5): 453-460.
Full papers/articles (Journal)
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz, G; Harrer, A; Oppermann, K; Wipfler, P; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Mult Scler. 2012; 18(4):506-509
Full papers/articles (Journal)
Future relevance of CSF biomarkers in modern MS treatment
Pilz, G; Wipfler, P; Harrer, A; Holl, B; Oppermann, K; Golaszewski, SM; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 383-388.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Natalizumab Treatment Effects Sustained Decrease in Serum Levels of Fibronectin and Soluble Adhesion Molecules sVCAM-1 and sICAM-3
Kraus, J; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A
NEUROLOGY. 2012; 78:
Abstracts (Journal)
Serum Levels of Soluble Adhesion Molecules Remain Stable during Short- and Long-Term Interferon-beta-1b Treatment
Kraus, J; Zaunrieth, R; Obregon-Castrillo, E; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Golaszewski, S; Hitzl, W; Trinka, E; Harrer, A
NEUROLOGY. 2012; 78:
Abstracts (Journal)
2011
Journal Articles
Carotid intima-media thickness, thrombin and atherosclersosis response
Bernhard, H; Wipfler, P
HAMOSTASEOLOGIE. 2011; 31(4A): S75-S76.
Letters
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Full papers/articles (Journal)
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21
Reviews
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J;
Mult Scler. 2011; 17(1):16-23
Full papers/articles (Journal)
Acute pulmonary edema caused by a multiple sclerosis relapse.
Wipfler, P; Pilz, G; Broussalis, E; Golaszewski, SM; Kunz, A; Trinka, E; Kraus, J;
J Neurol. 2011; 258(6): 1176-1179.
Letters
Conference papers, proceedings, abstracts
FUNCTIONAL INVOLVEMENT OF CEREBRAL CORTEX IN PATIENTS WITH SLEEP-WAKE DISTURBANCES AFTER TRAUMATIC BRAIN INJURY: A TMS STUDY
Golaszewski, S; Seidl, M; Kunz, A; Wipfler, P; Kraus, J; Nardone, R; Trinka, E; Gerstenbrand, F
EUR J NEUROL. 2011; 18: 57-57.
Abstracts (Journal)
Natalizumab binding to peripheral blood mononuclear cells analysed by flow cytometry can be used for monitoring treatment response in patients with multiple sclerosis
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Wipfler, P; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
J NEUROL. 2011; 258: 13-14.
Abstracts (Journal)
Anti-Inflammatory Effects of Copaxone on the Level of Adhesion Molecule Expression Patterns during Short- and Long-Term Treatment
Kraus, J; Oppermann, K; Harrer, A; Koczi, W; Duerr, EM; Wipfler, P; Pilz, G; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E
NEUROLOGY. 2011; 76(9): A384-A384.
Abstracts (Journal)
Flow Cytometry of Natalizumab Binding to Immune Cells and Its Potential Use for Monitoring Disease Activity and Treatment Response in Patients with Multiple Sclerosis
Kraus, J; Pilz, G; Einhaeupl, M; Oppermann, K; Wipfler, P; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A
NEUROLOGY. 2011; 76(9): A135-A136.
Abstracts (Journal)
Copaxone treatment shows anti-inflammatory effects on the level of adhesion molecule expression on peripheral blood mononuclear cells during short- and long-term therapy
Oppermann, K; Harrer, A; Koczi, W; Duerr, E; Wipfler, P; Pilz, G; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
J NEUROL. 2011; 258: 206-206.
Abstracts (Journal)
Newspaper/magazine articles
Isolated Leptomeningeal Infiltration of B-Cell Lymphoma Diagnosed by Flow Cytometry
Kraus, J; Oppermann, K; Wipfler, P; Harrer, A; Haschke-Becher, E; Afazel, S; Schonauer, U; Weis, SKiller-Oberpfalzer, M; Trinka, E
NEUROLOGY. 2011. 76 : A98-A98.
2010
Journal Articles
Relationship between thrombin generation and carotid intima-media thickness.
Bernhard, H; Wipfler, P; Leschnik, B; Novak, M; Kraus, J; Pilz, G; Ladurner, G; Muntean, W;
HAMOSTASEOLOGIE. 2010; 30 Suppl 1: S168-S171.
Full papers/articles (Journal)
Invasive aspergillosis presenting with a painless complete ophthalmoplegia
Wipfler, P; Pilz, G; Golaszewski, S; Luthringshausen, G; Berr, F; Kemmerling, R; Neureiter, D; Ladurner, G; Kraus, J
CLIN NEUROL NEUROSUR. 2010; 112(1): 85-87.
Case Reports
Conference papers, proceedings, abstracts
Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections
Kraus, J; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Afazel, S; Haschke-Becher, E; Kunz, AB; Golaszewski, SM; Staffen, W; Ladurner, G
NEUROLOGY. 2010; 74(9): A416-A416.
Abstracts (Journal)
Short- and long-term decrease of soluble adhesion molecules (sICAM-1,-2,-3 and sVCAM-1) during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Harrer, A; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S220-S220.
Abstracts (Journal)
Expression levels of cell surface bound interferon-receptor remain stable during short- and long-term interferon beta-1b treatment
Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Duerr, EM; Koczi, W; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S219-S219.
Abstracts (Journal)
Relationship between markers of endothelial damage and intima-media thickness in asymptomatic subjects
Wipfler, P; Bernhard, H; Leschnik, B; Pilz, G; Kraus, J; Muntean, W
J NEUROL. 2010; 257: S86-S86.
Abstracts (Journal)
Accumulation of natalizumab at the VLA-4 receptor as a potential molecular basis of enhanced treatment efficacy and occurrence of opportunistic infections
Wipfler, P; Oppermann, K; Pilz, G; Harrer, A; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S8-S8.
Abstracts (Journal)
2009
Journal Articles
Goat Cheese and Spondylodiscitis
Pilz, G; Hold, R; Wipfler, P; Iglseder, B; Hell, M; Golaszewski, S; Ladurner, G; Kraus, J
AKTUEL NEUROL. 2009; 36(8): 418-420.
Case Reports
Conference papers, proceedings, abstracts
Short-term decrease of soluble adhesion molecules during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Sulzer, C; Afazel, S; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S133-S133.
Abstracts (Journal)
Therapeutic effect of natalizumab despite the presence of neutralising antibodies shown by cell surface bound alpha4-integrin expression
Pilz, G; Wipfler, P; Oppermann, K; Sulzer, C; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S133-S133.
Abstracts (Journal)
Endogenous thrombin potential is associated with carotid intima-media thickness in subjects younger than 45 years
Wipfler, P; Bernhard, H; Pilz, G; Kraus, J; Afazel, S; Ladurner, G; Leschnik, B; Novak, M; Muntean, W
J NEUROL. 2009; 256: S51-S51.
Abstracts (Journal)
Natalizumab Treatment Leads to Changes in Adhesion Molecule Expression
Wipfler, P; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G; Kraus, J
NEUROLOGY. 2009; 72(11): A37-A38.
Abstracts (Journal)
Long-term effect of natalizumab on cell surface bound adhesion molecules expression
Wipfler, P; Pilz, G; Oppermann, K; Afazel, S; Huemer, M; Haschke-Becher, E; Staffen, W; Ladurner, G; Kraus, J
MULT SCLER. 2009; 15(9): S195-S196.
Abstracts (Journal)
2008
Journal Articles
Modern multiple sclerosis treatment - what is approved, what is on the horizon.
Pilz, G; Wipfler, P; Ladurner, G; Kraus, J;
Drug Discov Today. 2008; 13(23-24):1013-1025
Reviews
Klebsiella meningoencephalitis presenting like embolic ischemic stroke.
Wipfler, P; Pilz, G; Lesicky, O; Golaszewski, SM; Ladurner, G; Kraus, J;
J NEUROL. 2008; 255(12): 1983-1984.
Letters
Conference papers, proceedings, abstracts
Changes in adhesion molecule expression induced by natalizumab treatment in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G
MULT SCLER. 2008; 14: S133-S133.
Abstracts (Journal)
Influence of natalizumab treatment on a panel of cell surface bound adhesion molecules
Wipfler, P; Pilz, G; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G; Kraus, J
J NEUROL. 2008; 255: 211-211.
Abstracts (Journal)
Newspaper/magazine articles
Einfluss einer Therapie der Multiplen Sklerose mit Natalizumab auf die Expression von zellgebundenen Adhäsionsmolekülen
Kraus, J; Wipfler, P; Pilz, G; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G
Akt Neurol. 2008. 35 - P584: